SPDR SERIES TRUST - S&P PHARMAC (XPH)

Historical Holders from Q1 2014 to Q3 2025

Symbol
XPH
Type / Class
Equity / S&P PHARMAC
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
2,747,971
Holdings value
$131,750,198
% of all portfolios
0%
Number of holders
68
Number of buys
33
Number of sells
-26
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Institutional Holders of SPDR SERIES TRUST - S&P PHARMAC (XPH)

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q3 2,747,971 $131,750,198 -$3,633,998 $47.94 68
2025 Q2 2,870,725 $116,517,745 -$2,569,356 $40.58 65
2025 Q1 2,933,306 $128,452,608 +$30,259,828 $43.80 71
2024 Q4 2,351,364 $101,086,280 +$4,150,942 $42.99 74
2024 Q3 2,217,465 $98,364,631 -$21,671,561 $44.36 71
2024 Q2 2,649,945 $105,421,572 -$611,974 $39.78 72
2024 Q1 2,666,344 $114,994,244 -$11,070,727 $43.13 73
2023 Q4 2,925,100 $121,752,765 +$15,581,339 $41.62 72
2023 Q3 2,478,404 $98,566,489 -$16,603,407 $39.75 64
2023 Q2 2,842,974 $116,547,963 +$32,000,661 $40.99 58
2023 Q1 2,060,454 $84,527,079 -$23,583,901 $41.01 60
2022 Q4 2,637,629 $108,014,839 -$6,754,398 $40.95 70
2022 Q3 2,773,625 $111,461,206 +$9,885,713 $40.16 63
2022 Q2 2,518,460 $105,145,703 +$19,029,370 $42.00 69
2022 Q1 2,047,963 $92,724,799 -$12,017,657 $45.27 67
2021 Q4 2,303,245 $106,302,032 +$14,606,845 $46.15 75
2021 Q3 2,129,751 $101,049,767 -$2,207,669 $47.43 77
2021 Q2 2,166,494 $112,165,001 -$23,374,349 $51.76 79
2021 Q1 2,525,199 $127,084,457 -$10,716,279 $50.35 81
2020 Q4 2,718,819 $141,599,579 +$16,256,174 $52.06 79
2020 Q3 2,426,389 $105,360,785 -$12,416,925 $43.48 72
2020 Q2 2,716,053 $116,727,065 -$13,254,416 $42.98 71
2020 Q1 3,037,675 $109,582,279 -$50,151,759 $36.07 65
2019 Q4 4,896,880 $223,636,588 -$75,653,029 $45.67 75
2019 Q3 5,733,102 $204,044,462 +$64,175,230 $35.59 58
2019 Q2 3,879,938 $154,369,078 -$22,717,564 $39.83 59
2019 Q1 4,442,507 $184,712,034 +$33,192,286 $41.58 79
2018 Q4 3,859,537 $141,341,074 -$21,768,442 $36.62 70
2018 Q3 4,214,831 $204,391,820 +$32,481,115 $48.56 81
2018 Q2 3,588,107 $154,367,900 -$32,885,765 $43.01 68
2018 Q1 4,355,436 $182,384,285 +$53,712,705 $41.87 72
2017 Q4 2,984,321 $129,818,476 -$50,817,474 $43.50 82
2017 Q3 4,047,383 $172,153,949 +$1,755,771 $42.54 76
2017 Q2 4,002,762 $172,249,892 -$5,007,669 $43.03 77
2017 Q1 4,123,920 $172,487,399 +$14,291,081 $41.83 76
2016 Q4 3,800,844 $148,570,433 -$692,933 $39.09 75
2016 Q3 3,784,179 $167,240,636 +$3,100,968 $44.19 66
2016 Q2 3,721,168 $155,520,872 -$114,019,232 $41.79 58
2016 Q1 6,449,500 $259,443,359 +$46,323,699 $40.24 69
2015 Q4 5,294,999 $270,865,296 -$17,301,064 $51.20 74
2015 Q3 5,562,688 $261,379,549 +$115,697,114 $46.92 76
2015 Q2 2,805,077 $349,717,222 +$3,491,134 $124.70 82
2015 Q1 2,777,716 $342,726,354 -$7,428,997 $123.52 76
2014 Q4 2,859,697 $308,836,202 +$18,210,431 $107.96 75
2014 Q3 2,696,539 $285,736,613 -$52,635,552 $106.01 73
2014 Q2 3,200,366 $332,157,004 +$17,730,526 $103.80 69
2014 Q1 3,051,397 $285,644,847 +$10,204,820 $93.61 70